Vicks Sinex recalls in U.S., Europe
This article was originally published in The Tan Sheet
Procter & Gamble voluntarily recalls three lots of Vicks Sinex 15-mL nasal sprays marketed in Germany, the U.K. and the U.S. after finding the bacteria B. cepacia in products made at its facility in Gross Gerau, Germany. The firm says the recall is precautionary and no illnesses are reported, but the bacteria could cause serious infections for people with a compromised immune system or those with chronic lung conditions. P&G detected the bacteria during routine quality control testing and said analysis shows the problem is limited to a single batch of raw material mixture involving these lots: 9239028831 - Vapospray 12-Hour Decongestant Ultra Fine Mist in the U.S.; 9224028832 - Micromist Aqueous in the U.K.; and 9224028833 - Wick Sinex Schnupfenspray Dosiersystem in Germany
You may also be interested in...
Procter & Gamble recalls bonus packs of Vicks DayQuil Cold & Flu 24-Count LiquiCaps that lack child-resistant blister-pack backing. While otherwise safe for patients aged 12 and older, the product is labeled as having child-resistant packaging, the firm said Dec. 18. P&G recently recalled multiple lots of Vicks Sinex 15-mL nasal spray products due to possible bacterial contamination (1"The Tan Sheet" Nov. 23, 2009, In Brief)
CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.
The US FDA appears to have concerns about the device used to administer the vaccine.